Navigation Links
Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
Date:1/16/2008

etal pain is pain that affects the muscles, ligaments, and tendons. Acute musculoskeletal injuries are common and can occur during sports activities, exercise, or other physical activities. Acute musculoskeletal injuries generally require rapid treatment, which often includes the administration of anti-inflammatory drugs. Optimal topical treatment should relieve acute pain and reduce swelling in the injured area to restore normal movement. In addition, it should be safe and easy to administer.

Pain represents a large and dynamic market in the United States. Oral formulations of NSAIDs currently are marketed worldwide for the treatment of inflammation and pain, including pain due to musculoskeletal injuries, signs and symptoms of osteoarthritis and rheumatoid arthritis, menstrual cramps, headache and other minor aches and pains. While traditional oral NSAIDs are effective, they can cause serious gastrointestinal and other adverse events. Further, the withdrawal of some COX-2 inhibitors has removed a major therapeutic option for patients with multiple moderate and severe forms of pain, resulting in a significant market opportunity. These developments have created a significant need for a localized pain product with a strong safety profile.

About Cerimon Pharmaceuticals

Cerimon Pharmaceuticals, Inc., is a biopharmaceutical company dedicated to developing and commercializing therapeutic products for autoimmune diseases, inflammation and pain. Cerimon believes these new treatment options will enable physicians specialized in treating these conditions to further improve the lives of their patients.

Cerimon currently has two drugs in development. Simulect(R) (basiliximab) entered a Phase IIb study for moderate-to-severe steroid-refractory ulcerative colitis in April 2007. In addition, the Company has now initiated two Phase II/III studies of a topical patch formulation of diclofenac sodium in patients with acute musculoskeletal pain.

Ceri
'/>"/>

SOURCE Cerimon Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cerimon Pharmaceuticals Initiates Phase I Clinical Study of Topical Diclofenac Sodium Patch
2. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
3. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
6. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
7. Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa
8. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
9. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
10. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
11. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- Tianyin Pharmaceutical Inc. (NYSE Amex: ... the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), ... unaudited preliminary financial results for the first quarter ... 2015 Ended September 30, 2014 Financial Highlights: ... million in 1Q14 with gross margins improved to ...
(Date:12/24/2014)... FLINT, Mich. , Dec. 24, 2014  Diplomat ... largest independent specialty pharmacy, is proud to announce ... and quality at Diplomat, will take office as the ... 2015. The formal induction ceremony will take place Feb. ... which will be held at the Renaissance Center in ...
(Date:12/24/2014)... 23, 2014  Advanced Medical Isotope Corporation ("AMIC") ... in the development of brachytherapy devices and medical ... that it has filed a de novo ... ("FDA") for marketing clearance for its patented Y-90 ... U.S. Food, Drug and Cosmetic Act (the "Act").  ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3
... first time, an international panel of experts has ... Laparoscopic Sleeve Gastrectomy, a rapidly growing bariatric surgical ... The panel, made up of 25 ... help the surgical community continue to improve patient ...
... The report " In-Vitro Diagnostic (IVD) Market ... Emerging Markets   -   G7, Japan & BRIC) (2011 ... and studies the major market drivers, restraints, and opportunities in ... Browse market data tables and in-depth TOC ...
Cached Medicine Technology:International Panel of Leading Bariatric Surgeons Reaches Consensus on Optimal Techniques for Laparoscopic Sleeve Gastrectomy 2MarketsandMarkets: Global In-Vitro Diagnostic (IVD) Market Expected to Reach $64 Billion by 2016 2MarketsandMarkets: Global In-Vitro Diagnostic (IVD) Market Expected to Reach $64 Billion by 2016 3
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... YORK and DALLAS, Feb. 26 HealthpointCapital, LLC.,("HealthpointCapital") ... H.,Hochschuler as Clinical Advisor to the Firm. HealthpointCapital ... focused on,orthopedic and dental device companies. Dr. Hochschuler ... of Texas Back Institute Holdings and,Chairman of the ...
... Feb. 26 Local communities,can be effective in ... diabetes and heart disease if they use healthy ... strategic principles identified by,leading national programs., Communities ... the nation. There are eight leading national programs ...
... as Chairman of the Board of Directors; Daniel ... to Chief Operating Officer -, EXTON, Pa., Feb. 26 ... 2008, Vincent J.,Milano will succeed Michel de Rosen as president and ... board of directors. Mr.,de Rosen, who has led the company as ...
... 27% of their income after diagnosis , , TUESDAY, Feb. 26 ... with breast cancer, working women lose an average of 27 ... from Laval University in Quebec interviewed 829 women at one, ... women were asked a number of work-related questions, such as ...
... CHICAGO -- Millions of cancer patients take drugs to ... become anemic after chemotherapy. But a new study by ... called erythropoiesis-stimulating agents (ESAs), actually raise patients, risk of ... , A meta-analysis of 51 trials with 13,613 ...
... DIEGO, Feb. 26 AMN Healthcare Services,Inc. (NYSE: ... revenue for the fourth quarter of 2007 of $285.9 ... million reported for the,same quarter last year, and a ... the third quarter. The sequential decline in revenue,was due ...
Cached Medicine News:Health News:HealthpointCapital, LLC Appoints Stephen H. Hochschuler, M.D. as Clinical Advisor 2Health News:Effective Healthy Eating and Physical Activity Initiatives Can Reduce Health Disparities 2Health News:Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma 2Health News:Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma 3Health News:Cost of Breast Cancer Can Include Paycheck 2Health News:Drug for anemic cancer patients raises risk of death 2Health News:Drug for anemic cancer patients raises risk of death 3Health News:AMN Healthcare Reports Fourth Quarter and Year End 2007 Results; Provides Full Year 2008 Guidance 2Health News:AMN Healthcare Reports Fourth Quarter and Year End 2007 Results; Provides Full Year 2008 Guidance 3Health News:AMN Healthcare Reports Fourth Quarter and Year End 2007 Results; Provides Full Year 2008 Guidance 4Health News:AMN Healthcare Reports Fourth Quarter and Year End 2007 Results; Provides Full Year 2008 Guidance 5Health News:AMN Healthcare Reports Fourth Quarter and Year End 2007 Results; Provides Full Year 2008 Guidance 6Health News:AMN Healthcare Reports Fourth Quarter and Year End 2007 Results; Provides Full Year 2008 Guidance 7Health News:AMN Healthcare Reports Fourth Quarter and Year End 2007 Results; Provides Full Year 2008 Guidance 8Health News:AMN Healthcare Reports Fourth Quarter and Year End 2007 Results; Provides Full Year 2008 Guidance 9Health News:AMN Healthcare Reports Fourth Quarter and Year End 2007 Results; Provides Full Year 2008 Guidance 10Health News:AMN Healthcare Reports Fourth Quarter and Year End 2007 Results; Provides Full Year 2008 Guidance 11Health News:AMN Healthcare Reports Fourth Quarter and Year End 2007 Results; Provides Full Year 2008 Guidance 12Health News:AMN Healthcare Reports Fourth Quarter and Year End 2007 Results; Provides Full Year 2008 Guidance 13Health News:AMN Healthcare Reports Fourth Quarter and Year End 2007 Results; Provides Full Year 2008 Guidance 14Health News:AMN Healthcare Reports Fourth Quarter and Year End 2007 Results; Provides Full Year 2008 Guidance 15
GENios Pro, TECANs advanced, multi-functional injector reader offers simultaneous reagent dispensing and detection for monitoring of fast kinetic reactions...
... for Ultra High Throughput Screening (UHTS), ... detection performance. Allows for smooth transfer ... development by sharing all the detection ... fluorescence intensity, fluorescence polarization, time-resolved fluorescence, ...
... The POLARstar OPTIMA is a ... which incorporates five different measurement principles:, ... Intensity , Time-Resolved Fluorescence , ... , Absorbance ,It is ...
... solution to cell based assays, in 6 ... method of detection, Fusion is the instrument ... the capability to use the AlphaScreen assay ... in one system: Reads AlphaScreen (Amplified ...
Medicine Products: